Abstract: 【Abstract】Objective To evaluate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) on treating patients with relapsed or refractory T-lymphoblastic lymphoma (TLBL). Methods 16 patients with TLBL were long-term followed-up and analyzed retrospectively. The major conditioning regimens were BEAM and BEAC. Results 15 patients were evaluable for efficacy and 1 patient lost in follow-up. The median progression-free survival (PFS) was 34.5 months. The expecting median overall survival time (OS) was 49 months. The rates of 1-，3-and 5-year OS were 60%，53% and 32% respectively. Among the newly diagnosed patients who were effectively first -line treated，the median OS was 108 months，the rates of 5-year OS and PFS were 62% and 63% respectively. Among the patients who had response after first-line treatment，the median OS was 22.8 months，the rates of 5-year OS and PFS were 33% and 22% respectively. Median OS for the heavily-treated or refractory patients was 21 months，the rates of 5-year OS and PFS were 20% and 29% respectivelyConclusionsAHSCT is effective and safe for TLBL after conventional chemotherapy. It can improve long-term survival and extend PFS on the initial treated patients，though the recurrent rate remains relatively high. Large-scale clinical trial is urgently warranted.

Key words: 【Key words】Lymphoma, Autologous hematopoietic stem cell transplantation, Lymphoblastic lymphoma